Students and staffPhilanthropyMedia

The PERSIST project has been going on for more than a year

In January 2020, the PERSIST project was launched under the leadership of the Spanish ICT Technology Center Gradiant in cooperation with the Institute of Clinical and Preventive Medicine of the University of Latvia and eleven other partners.

The expertise of the PERSIST project partners is being combined to develop an innovative platform that will support physicians in making decisions aimed at improving care for patients after cancer treatment.
In late 2020 and early 2021, the technical partners of the PERSIST project are developing the first version of the mHealth patient application. It will monitor important indicators of patients' health, such as sleep, heart rate, physical activity, while offering to fill in various surveys and obtain information about a person's emotional state. At the same time, intensive work is being done on the preparation of various informative materials. They will help the people included in the study to better understand the nature of the project, as well as the possibilities of using the app, smartphone and smartwatch. A short informative brochure, a smart process user manual and a short video with instructions on how to use the smart watch have already been prepared and translated into several languages, including Latvian. It is planned to start enrolling patients in the PERSIST pilot study in the spring. Participants will receive a smartwatch and a smartphone with the new mHealth application installed, which will provide a variety of data acquisition and then customize patient care.

The study, based on the use of artificial intelligence and big data to improve the health sector, involves 13 partners from 10 different countries: Spain, Italy, Austria, Bulgaria, Slovenia, Latvia, Switzerland, Portugal, Belgium and Turkey. The project is funded by the European Union under Horizon 2020 and has a total budget of more than 5 million euros.
Within the framework of the PERSIST project, the Institute of Clinical and Preventive Medicine of the University of Latvia ensures the management of the clinical trial. It will take place in four hospitals in Belgium, Latvia, Spain and Slovenia.

 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 875406

Share